2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer Database
2015
Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas
Jairam V, Rutter C, Yu J, Bindra R. Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. Journal Of Radiation Oncology 2015, 4: 163-167. DOI: 10.1007/s13566-015-0193-8.Peer-Reviewed Original ResearchAdjuvant chemotherapyAnaplastic astrocytomaRT volumeAnaplastic gliomasGlioma patientsMaximal responseAnaplastic glioma patientsRadiotherapy treatment volumesStable diseaseSalvage radiotherapyPathologic factorsHospital recordsChemotherapyPatientsIndependent sample t-testRadiotherapyTarget volumePercentage changeVolumetric reductionTreatment volumeSample t-testProgressionT-testGliomasSalvage